Jul 10, 2012 by Brian Orelli, PhDThe FDA's Plan to Reduce Drug SalesFDA issues a painful directive to companies selling opioids.
Jul 2, 2012 by Brian Orelli, PhDWhy This Joint-Venture Buyout Is Good for InvestorsBristol-Myers Squibb and AstraZeneca team up to buy Amylin.
Jun 29, 2012 by Brian Orelli, PhDThe World's Best Innovation That Isn't Worth Investing In The value in human genome sequencing isn't in doing it again.
Jun 29, 2012 by Brian Orelli, PhDSlice and Dice Data and Investors Will Slice YouBiotechs should take a lesson from Vertex.
Jun 28, 2012 by Brian Orelli, PhDThere Goes Half of Arena's MarketThere's more than meets the press release's eye.
Jun 28, 2012 by Brian Orelli, PhDNot All of Obamacare Was UpheldAnd it could be bad for these companies.
Jun 27, 2012 by Brian Orelli, PhDApproval! Hefty Increase for Arena's SharesThe FDA approves Arena's obesity drug Belviq.
Jun 26, 2012 by Brian Orelli, PhDIt's Hard to Sell a Drug Like ThatPfizer and Bristol-Myers Squibb fail to get Eliquis approved.
Jun 26, 2012 by Brian Orelli, PhDHow the Obamacare Verdict Could Crush DrugmakersAll the heartache with none of the fun.
Jun 25, 2012 by Brian Orelli, PhDAre Teva's Pop and Momenta's Crash Overreactions?A court upholds the patents on Copaxone.
Jun 25, 2012 by Brian Orelli, PhDApprovable, Just Not ApprovedThe EU recommends against Protalix and Pfizer because of a competing orphan drug.
Jun 23, 2012 by Brian Orelli, PhDNo Delay for Arena?If it was going to happen, it seems as if it should have already.
Jun 22, 2012 by Brian Orelli, PhDLosing the Battle and the WarFDA turns down Johnson & Johnson's Xarelto, and more competition could be on the way.
Jun 21, 2012 by Brian Orelli, PhDUp 40%! Is Approval a Done Deal?Onyx's carfilzomib gets a ringing endorsement.
Jun 21, 2012 by Brian Orelli, PhD1 Big Growth Driver WithdrawnCelgene pulls its EU marketing application for Revlimid.
Jun 20, 2012 by Brian Orelli, PhDProfit From the Next Innovative Class of DrugsRNAi looks like a good candidate.
